Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
about
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virusCytidine deamination induced HIV-1 drug resistanceLamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acidsSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineDynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencingIncreased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineWild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidineTemporal and spatial analysis of Sin Nombre virus quasispecies in naturally infected rodentsYADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.Genotypic testing for human immunodeficiency virus type 1 drug resistance.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymeraseVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site.The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineCompensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsSubunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Constructive neutral evolution: exploring evolutionary theory's curious disconnect.Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid.Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.Selection of T1249-resistant human immunodeficiency virus type 1 variants.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.Drug resistance in HIV-1.A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control.Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase.The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
P2860
Q24498670-875EAE91-C013-4614-9885-3ACDFD755605Q24657298-A8EA6AFE-B755-4937-A92F-B10EC09ED7BAQ24682078-807A9624-E502-42E4-8FBD-DD4695823700Q28344137-0D517A19-E29B-445B-BBC7-8E3FF52D8C3AQ28474783-7B49CD0F-2898-43EC-AC7F-38B4171DDD14Q33737755-5D6BF4D2-0672-4A44-B4B0-E121E7516F12Q33782477-D1A6DE3D-D02F-43BB-B7C6-6510B9CA38AFQ33808236-630BD26F-704C-417C-AB4E-E3AFD73C4DC3Q33823575-09B9EA9C-BD92-4508-8BDF-C7B60E496ED0Q33842803-9285D02E-94D0-4B4F-9D6A-2F6CD19115A5Q33906239-C3C68A1D-B9E0-4B6F-B1C5-5566B9331B62Q33979107-F177EF93-3563-417A-B9DA-D33F93F481BDQ34115561-4EB44765-6DE4-4B69-A266-78CA156789C5Q34339657-0A975187-BE2D-4600-8CBA-C743BBDF6A3FQ34434986-43B48FFB-A97E-40C7-8538-FF76A7AF3F5AQ34668716-16A9836A-B552-4970-85B2-4FCCEC960021Q35139503-5DC0B2D2-03EF-4D6D-BA76-866FB15480E0Q35363054-C918A384-8D43-48C3-93E7-8B65104CB32DQ35363594-80033EDC-E160-4955-B6A0-6D79FE4AD0CAQ35566910-5242DAF8-8175-4DF4-B29D-D01288D5C1C6Q35636029-2333F538-4B5F-48AF-8AFF-1F362D790AD6Q36172087-E17BDCE5-F471-4D39-8E33-B013A3A15E11Q36500717-A056E128-9F95-46B9-9162-765BEB28A0D9Q36673297-1DA0F4BE-A34F-46E9-980E-55ABB303B79EQ36684283-54FC393D-4828-4F33-8BF2-5752D544CFA6Q36748009-EC29A0A5-96D4-44ED-8378-BEA8AE421F4FQ36969977-85B9C3A3-5ABD-4A8E-93D6-CE1E780937D4Q37072022-344D7DF4-B15E-4641-9E25-D0518ED983CAQ37596642-A31AD1CA-F77F-4620-834E-5E894113D9A9Q37620810-E9426E10-E9E3-4A86-96DC-0FD7D9057734Q37755873-BB3DA11F-99DA-4B95-9A41-CAC4BC1B15EBQ37967710-426D41CA-36CD-4ADE-9D26-A120C820E455Q38759997-642F9296-9809-45A3-B816-479F211F6A83Q39136662-C587FB87-D4A2-44D1-B8BC-B2BE9540CC81Q39591902-E11ACB8C-FD36-41E4-A34B-788CAFE837BEQ39603104-E2700088-227B-4EEA-A63C-18FB0B893C94Q39689383-54622A53-1466-4DAF-BB6A-609CFE63C3ABQ39720877-B73899E8-87B3-489F-A4FC-8B8BF1D68C96Q39776171-B5AD418D-D79F-45F6-BA73-27A0431E82E2Q39785298-19EAAF59-620A-4AB4-9CF9-C4739D941D45
P2860
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Initial appearance of the 184I ...... s type 1 reverse transcriptase
@en
Initial appearance of the 184I ...... type 1 reverse transcriptase.
@nl
type
label
Initial appearance of the 184I ...... s type 1 reverse transcriptase
@en
Initial appearance of the 184I ...... type 1 reverse transcriptase.
@nl
prefLabel
Initial appearance of the 184I ...... s type 1 reverse transcriptase
@en
Initial appearance of the 184I ...... type 1 reverse transcriptase.
@nl
P2093
P2860
P1433
P1476
Initial appearance of the 184I ...... s type 1 reverse transcriptase
@en
P2093
P2860
P304
P407
P577
1997-04-01T00:00:00Z